First widely announced public information regarding a novel coronavirus.
World Health Organisation officially declares a global pandemic.
Academics, scientists and clinicians work to create a master protocol for the AGILE platform study.
The AGILE platform receives the go ahead to prepare sites for opening.
The first commercial pharmaceutical company joins the AGILE platform.
The Liverpool site is open to start recruiting.
First patient receives the first therapeutic to be trialled through the AGILE platform.
UNITAID agree to support the work of the AGILE platform.
Two new therapies to be tested for COVID-19
Our mission is to shorten the time taken to identify safe, effective and affordable treatments for COVID-19.
AGILE will be the key link in the chain of accelerated drug development, evaluating potential candidate treatments for COVID-19 and advancing only the compounds most likely to be effective into large-scale clinical trials.
As citizens and as academic researchers, we seek new and effective treatments for COVID-19 as quickly as possible, made readily available to all who need it. We recognise the importance of generating research data which are robust, reproducible, timely, of high quality and used for public good.
We will apply the following considerations which reflect our core values (and those of our funders) and the public nature of our core funding:
- Patient benefit is our utmost priority and everything we do is for the ultimate benefit of patients.
- We will not compromise on quality as we create the evidence for better therapeutics quickly.
- We do not seek to make any financial profit from the AGILE platform. Our costs are calculated using published UK HEI (academic) and NIHR models.
- AGILE is designed as an open resource. Our Master Protocol, and associated templates for candidate-specific trial arms are published, and freely available for use by other researchers (at their own risk).
- The AGILE Sponsor retains the rights to all data generated from our clinical research activity. This is important for the purposes of Research and Education, but also for sharing data across arms (as is the purpose of any platform trial), for depositing anonymised data in large shared repositories, and for use by other researchers.
- Collaboration to find promising drug candidates is the lifeblood of our Programme. We actively seek discussions with the pharmaceutical and biotechnology industry, with other academic researchers, public consortia and global healthcare stakeholders.
- We believe that public-private collaborative partnerships can be a win-win for all, and fully support the need for industry to develop commercially viable products. We also believe that COVID-19 poses one of the greatest global humanitarian threats in our lifetime; there is both a humanitarian and an ethical imperative to make effective treatments available to all, and especially to ensure equitable and affordable access for low- and middle-income countries.
- We take our candidate prioritisation process seriously. Our independent Scientific Advisory Board oversees this process, which takes into account the strength and quality of supporting evidence as well as our capacity to undertake any trial. We may also not pursue candidates which do not meet our criteria for scalable, and affordable access. It is never our intention to stop any potential medicine from undergoing investigation and we seek only to prioritise our limited resources to opportunities that stand the best chance of success.